Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George L Melikian

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Immunological Investigations|October 12, 2011
Aspergillosis in the 'nonimmunocompromised' hostDavid A Stevens, George L Melikian
Antimicrobial Agents and Chemotherapy|June 6, 2012
Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirineMaya Balamane, Vici Varghese, George L Melikian, et al.
Antimicrobial Agents and Chemotherapy|June 26, 2013
Prototypical Recombinant Multi-Protease-Inhibitor-Resistant Infectious Molecular Clones of Human Immunodeficiency Virus Type 1Vici Varghese, Yumi Mitsuya, W Jeffrey Fessel, et al.
Antimicrobial Agents and Chemotherapy|February 15, 2012
Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibilityGeorge L Melikian, Soo-Yon Rhee, Jonathan Taylor, et al.
The Journal of Antimicrobial Chemotherapy|August 13, 2013
Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testingGeorge L Melikian, Soo-Yon Rhee, Vici Varghese, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Immunological Investigations|October 12, 2011
Aspergillosis in the 'nonimmunocompromised' hostDavid A Stevens, George L Melikian
Antimicrobial Agents and Chemotherapy|June 6, 2012
Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirineMaya Balamane, Vici Varghese, George L Melikian, et al.
Antimicrobial Agents and Chemotherapy|June 26, 2013
Prototypical Recombinant Multi-Protease-Inhibitor-Resistant Infectious Molecular Clones of Human Immunodeficiency Virus Type 1Vici Varghese, Yumi Mitsuya, W Jeffrey Fessel, et al.
Antimicrobial Agents and Chemotherapy|February 15, 2012
Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibilityGeorge L Melikian, Soo-Yon Rhee, Jonathan Taylor, et al.
The Journal of Antimicrobial Chemotherapy|August 13, 2013
Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testingGeorge L Melikian, Soo-Yon Rhee, Vici Varghese, et al.
Pageof 1